Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial


Panaccione R., Colombel J., Travis S. P. L. , Bossuyt P., Baert F., Vanasek T., et al.

GUT, cilt.69, ss.658-664, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 69 Konu: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1136/gutjnl-2019-318256
  • Dergi Adı: GUT
  • Sayfa Sayısı: ss.658-664

Özet

Objective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn's disease (CD) naive to immunosuppressants and biologics using a UK public payer perspective.